16 June 2023 - The outcomes from the May 2023 PBAC intracycle meeting are now available.

The following medicines were recommended:

• Carmellose sodium with glycerin and hyaluronic acid (Optive Fusion) - lowest cost alternative
• Darolutamide (Nubeqa) - new indication
• Hyaluronic acid with polyethylene glycol 400 with propylene glycol and hydroxypropyl guar (Systane Hydration) - lowest cost alternative
• Fluticasone propionate (Axotide Junior, Flixotide Junior) - restriction change
• Inclisiran sodium (Leqvio) - new medicine (lower price offered)
• Pembrolizumab (Keytruda) - restriction change

The PBAC also recommended:

• Dasatinib monohydrate - restriction change (no submission)
• Imatinib mesylate - restriction change (no submission)
• Meningococcal Group B vaccine (multicomponent) (Bexsero) - restriction change (ATAGI advice)

Read PBAC outcomes